Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez
{"title":"[皮肤试验证明对辉瑞- biontech®疫苗过敏]。","authors":"Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez","doi":"10.29262/ram.v69i2.1088","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.</p><p><strong>Case report: </strong>30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.</p><p><strong>Conclusions: </strong>An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"69 2","pages":"89-92"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].\",\"authors\":\"Carlos David Estrada-García, Ana Paola Macías-Robles, Rosa María Cortés-Grimaldo, Hilda Lilian Carvajal-Alonso, Marlen Barreto-Alcalá, Adriana Ramírez-Nepomuceno, David Esparza-Amaya, Kareli Guadalupe Coronado-Hernández, Britza Barrios-Díaz, Héctor Hugo Campos-Téllez\",\"doi\":\"10.29262/ram.v69i2.1088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.</p><p><strong>Case report: </strong>30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.</p><p><strong>Conclusions: </strong>An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.</p>\",\"PeriodicalId\":21175,\"journal\":{\"name\":\"Revista alergia Mexico\",\"volume\":\"69 2\",\"pages\":\"89-92\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista alergia Mexico\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29262/ram.v69i2.1088\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v69i2.1088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].
Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.
Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.
Conclusions: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
